Kinase-Targeted Therapeutics Market: Overview
Kinase is an enzyme class that helps to transfer phosphate groups to certain substrate from high energy molecules such as adenosine triphosphate (ADP). This phenomenon of phosphate group transfer is termed as phosphorylation. Kinases control various cellular activities such as cell signaling, cellular transport, protein regulation, secretory processes and cellular metabolism. Based on the molecule on which kinases act, they can be categorized as: protein kinase, lipid kinase, carbohydrate kinase and other kinase (thymidine kinase and riboflavin kinase). Protein kinases include mitogen activated protein kinases and cyclin dependent kinases. Lipid kinases include sphingosine kinases and phosphatidylinositol kinases.
Protein kinase acts on tyrosine, serine, histidine or threonine content of protein and modify the protein functionality by either increasing or decreasing their activities. Lipid kinase acts on the cell or plasma membrane along with organelles membrane. Activity of kinase on membrane helps alter reactivity of lipids and hence result in signal transmission. Carbohydrate kinases (hexokinase and phosphofructokinase) act on bisphosphoglycerate and other carbohydrate molecule to release energy. Among all the aforementioned kinases, protein kinases therapeutics accounts for the largest share of the total market owing to their wider application area coupled with their large utilization in developing and manufacturing therapeutic drugs.
Many diseases are caused due to inappropriate activities of kinases. Aberrant kinase activities also results in proliferative or inflammatory responses for the diseases such as cancer and rheumatoid arthritis. Kinase activities have also resulted in cardiovascular diseases, diabetes and neurological disorders. Hence, any disruption in the activities of any of the kinase may result in adverse effects on the people. Kinase-targeted therapeutics include all those drugs that act on the kinases that are affecting negatively to the people. These drugs enable the physicians to treat the disease from the root cause and help eliminating the adverse effects of the disease.
Browse full report on Kinase-Targeted Therapeutics Market – http://www.transparencymarketresearch.com/kinasetargeted-therapeutics-market.html
Kinase-Targeted Therapeutics Market: Driving Forces
Owing to rising incidences of diabetes the population, the market for kinase-targeted therapeutics is poised to grow at a significant CAGR from the period 2013 to 2019. The World Diabetes Foundation (WDF) has estimated that nearly 285 million populace lived with diabetes in the year 2010 that accounted for 6.4% of the world’s youth population in the same year. This number is poised to grow to 438 million by 2030, corresponding to 7.8% of the world’s adult population. The National Diabetic Fact Sheet of the U.S., which was released in January 2011, states that 25.8 million children and adults suffer from diabetes which accounts for 8.3% of the total U.S. population.
Almost 1.9 million new cases were diagnosed in people aged 20 years and above in the U.S. alone. Similarly, increasing number of cancer patients across the globe also augments the growth of kinase-targeted therapeutics market. It has been estimated by the World Cancer Research Fund International that by 2030 around 21 million people will suffer from cancer worldwide.
Kinase-Targeted Therapeutics Market: Regional Dynamics
In 2012, North America accounted for the largest share of global kinase-targeted therapeutics market owing to presence of large geriatric population. Elder people are prone to various diseases such as cardiovascular diseases and other that can be easily treated by the uptake of kinase-targeted therapeutic drugs.
Similarly, domicile of big manufacturers of kinase-targeted therapeutic drugs in the region has further supported the large market size of kinase-targeted therapeutics market. The major players operating in kinase-targeted therapeutics market include Abbott Laboratories, Eli Lilly and Company, Array BioPharma, Inc., Avila Therapeutics, Inc. and Bristol-Myers Squibb Co amongst other significant players.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Request for brochure of this report – http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11468
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453